Associate Prof. of Bioengineering, University of Pisa, Head of In-Vitro Models Group and NanoBioscopy Lab at the National Council of Research Institute of Clinical Physiology (CNR-IFC). Also involved in capacity building in the field of Biomedical Engineering, in association with UNECA and FABLAB Pisa .Author of over 100 peer-reviewed publications and of several patents on microfabrication and on bioreactors, co-founder of 2 high-tech companies.
Training: Dental Research, Bioengineering.
Postdoctoral: TGF-beta, wound healing, regeneration, radiation biology, light biology, stem cells, biomaterial, Lasers.
Current: Clinical translational research and Molecular mechanisms.
Positions: President, NAALT; Chair SPIE, Chair ALD; Chair ASLMS.
Interests: Signal Transduction, Lasers, Biological regulation.
Director of the Cambridge Centre for Neuropsychiatric Research at Cambridge University. Practising clinician (with an Honorary Consultant position in General Adult Psychiatry at Addenbrookes Hospital, Cambridge). Co-founder of Psynova Neurotech Ltd. Professor for Tranlational Neuroscience at Erasmus University Medical Centre, Department of Neuroscience, Rotterdam.
Group Leader, Structural Biochemistry in Institute of Complex Systems (ICS-6) in Research Centre Juelich, Germany. Postdoctoral scientist at the Max Planck Institute for Medical Research, Heidelberg, Germany (1996-1999) and at Columbia University, New York, USA (1999-2002). Primary focus of my research is to understand the structure-function relationships of soluble and membrane proteins of biological importance.
Professor, Wishner Chair of Bio-organic Chemistry. Early development of avidin-biotin technology. Co-discoverer of the cellulosome concept. Editor/Editoral Board: Biotechnology Advances, Biotechnology for Biofuels, Current Opinion in Biotechnology, Industrial Biotechnology. Member of Scientific Advisory Board, US-DOE BioEnergy Science Center (BESC). Sarstedt Research Award, The Ulitzky Prize, Fellowship of the American Academy of Microbiology and European Academy of Microgiology.
Professor of Biology at the University of Antwerp. Member of the Flemish Science Foundation review board. Editor of the journals Journal of Plant Research, Frontiers in Plant Science and PLOS ONE
Max Planck Research Group Leader since 2014; assistant professor at Radboud University Nijmegen; PostDocs at University of Leuven and University of Strasbourg; PhD in Biophysics from Ludwig Maximilian University Munich; Research interests: mechanobiology, molecular force sensors, protein engineering, single molecule techniques (force and fluorescence); Editor of Biophysical Reviews and Letters
Inserm Researcher in the field of Cardiovascular Research, currently focusing on therapeutic angiogenesis with polymer-based targeted growth factor delivery.
PhD in Tumor Biology (Pr Yihai Cao, Karolinska Institutet, Sweden), and expertise in Adipose tissue angiogenesis. Postdoc at UCLA (Pr Lily Wu) in molecular imaging and tumor lymphangiogenesis field.
Member of European Vascular Biology Organisation, French society for Cardiovascular Research, French society for Angiogenesis Research.
I am currently a Chief Investigator in the ARC Centre of Excellence in Plant Cell Walls, based at the University of Adelaide. I undertook my PhD at the John Innes Centre, Norwich. My expertise is in the areas of plant molecular biology particularly as it relates to cell wall biosynthesis, re-modeling and degradation and how these impact cereal end use quality. I also have an interest in the development and application of novel experimental methods for transcript profiling and gene discovery.
Associate Professor of Medical Engineering, Mechanical Engineering at The University of Hong Kong.
Professor, School of Life Sciences, Tsinghua University, Beijing. Over 23 issued patents and 30 pending patents.
Albert Cheng obtained his BSc in Biochemistry and MPhil in Biology from Hong Kong University of Science and Technology in 2005 and 2007, respectively. He studied neurotrophin signaling and C. elegans developmental genetics. He then pursued his PhD in Computational & Systems Biology at MIT in the labs of Profs Christopher Burge and Rudolf Jaenisch and worked on various topics on epigenetics, gene regulation and alternative splicing in stem cells, reprogramming, cancer metastasis, erythropoiesis and differentiation. Cheng and colleagues identified H3K27ac as a signature for active enhancers. He analyzed alternative splicing in epithetlial-mesenchymal transition, cancer metastasis as well as erythropoiesis and identified splicing factors regulating these processes. He constructed CRISPR-on, an artificial RNA-guided activator based on CRISPR/Cas. After graduating in 2014, he joined the Jackson Laboratory at Bar Harbor, ME, as one of the first JAX scholars where he continued to work on understanding and improving the CRISPR/Cas technology. In July 2015, he started his own lab as an assistant professor at the Jackson Laboratory for Genomic Medicine campus at Farmington, CT.